ArticleFrontiers in microbiology2016
Norovirus-Specific Memory T Cell Responses in Adult Human Donors.
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant.Frontiers in immunology · 2023Trial
- Characterization of humoral and cellular immunity induced by mRNA vaccines expressing norovirus VP1 proteins in mice and NHPs.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Current Perspectives and Future Directions in the Immunogenicity Landscape of Norovirus Vaccines.Journal of microbiology and biotechnology · 2025Review
- Characteristics of Norovirus capsid protein-specific CD8Virulence · 2024Article
- Article
- Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses.Journal of virology · 2024Article
- Clinical and In Vitro Evidence Favoring Immunoglobulin Treatment of a Chronic Norovirus Infection in a Patient With Common Variable Immunodeficiency.The Journal of infectious diseases · 2022Article
- Advances in Human Norovirus Vaccine Research.Vaccines · 2021Review
- The dark side of the gut: Virome-host interactions in intestinal homeostasis and disease.The Journal of experimental medicine · 2021Review
- Human rhinovirus-specific CD8 T cell responses target conserved and unusual epitopes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only.Vaccines · 2020Article
- Generation of Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy.The Journal of infectious diseases · 2020Article
- Article
- Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced inPharmaceutics · 2019Article
- Review
- Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Development of T cell immunity to norovirus and rotavirus in children under five years of age.Scientific reports · 2019Article
- Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 Variant.Viruses · 2019Article
- Article
- Identification of a First Human Norovirus CD8Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Norovirus (NoV) is a leading cause of acute gastroenteritis in people of all ages worldwide. NoV-specific serum antibodies which block the binding of NoV virus-like particles (VLPs) to the cell receptors have been thoroughly investigated. In contrast, only a few publications are available on the NoV capsid VP1 protein-specific T cell responses in humans naturally infected with the virus. Freshly isolated peripheral blood mononuclear cells of eight healthy adult human donors previously exposed to NoV were stimulated with purified VLPs derived from NoV GII.4-1999, GII.4-2012 (Sydney), and GI.3, and IFN-γ production was measured by an ELISPOT assay. In addition, 76 overlapping synthetic peptides spanning the entire 539-amino acid sequence of GII.4 VP1 were pooled into two-dimensional matrices and used to identify putative T cell epitopes. Seven of the eight subjects produced IFN-γ in response to the peptides and five subjects produced IFN-γ in response to the VLPs of the same origin. In general, stronger T cell responses were induced with the peptides in each donor compared to the VLPs. A CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.